Quick Answer
PALISADE BIO, INC. reported Diluted EPS of $0.30 per share (loss) for fiscal year 2025.
PALISADE BIO, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.30 | +97.1% |
| 2024 | -$10.19 | +62.3% |
| 2023 | -$27.01 | -63.4% |
| 2022 | -$16.53 | +90.3% |
| 2021 | -$169.74 | -4462.9% |
| 2020 | -$3.72 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.38 | +83.6% | +34.5% |
| June 30, 2025 | -$0.58 | +82.5% | -23.4% |
| March 31, 2025 | -$0.47 | +89.8% | +79.7% |
| September 30, 2024 | -$2.32 | +68.6% | +30.1% |
| June 30, 2024 | -$3.32 | +58.1% | +27.7% |
| March 31, 2024 | -$4.59 | +43.5% | +37.8% |
| September 30, 2023 | -$7.38 | -80.0% | +6.9% |
| June 30, 2023 | -$7.93 | -37.4% | +2.5% |
- PALISADE BIO, INC. showed an increase of +97.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, PALISADE BIO, INC.’s diluted eps has grown by 91.9% (from $3.72 per share (loss) to $0.30 per share (loss)).
- The most recent figure is from PALISADE BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: